Can norethisterone (Primolut N) be used to stop prolonged vaginal bleeding due to anovulatory dysfunctional uterine bleeding in a 14‑year‑old girl?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Norethisterone (Primolut N) Be Used for Anovulatory Dysfunctional Uterine Bleeding in a 14-Year-Old?

Yes, norethisterone (Primolut N) can be used to stop prolonged vaginal bleeding due to anovulatory dysfunctional uterine bleeding in a 14-year-old girl, administered as oral progestin therapy for 10-14 days per month. 1, 2

Treatment Approach for Adolescent Anovulatory Bleeding

First-Line Medical Management

  • Oral progestins are the appropriate treatment for anovulatory dysfunctional uterine bleeding in adolescents, with norethisterone being an acceptable second-choice progestin option 3

  • The standard regimen is norethisterone 5-10 mg three times daily from day 12-25 of the cycle (or medroxyprogesterone acetate 10 mg daily for 10-14 days per month), which effectively reduces menstrual blood loss and controls bleeding patterns 1, 2

  • For adolescents specifically, medroxyprogesterone acetate administered orally once daily for 10 days each month for ≥3 months is the recommended approach, with close monitoring thereafter 2

Important Clinical Considerations

  • Micronized progesterone (MP) is the first-choice progestin when available due to lower cardiovascular and thrombotic risk, with norethisterone, medroxyprogesterone acetate (MPA), and dydrogesterone as second choices 3

  • Norethisterone requires a minimum dose of 1 mg daily for continuous regimens or higher doses (5-10 mg three times daily) for cyclical treatment of acute bleeding 3, 1

  • The treatment goal is to stop acute bleeding, prevent future episodes, and prevent long-term complications including endometrial hyperplasia from unopposed estrogen 4, 5

Acute vs. Chronic Management

  • For acute heavy bleeding episodes, high-dose estrogen therapy may be needed first, followed by progestin stabilization 2

  • For chronic anovulatory bleeding in adolescents, cyclical progestin therapy (10-14 days per month) is the foundation of treatment, avoiding continuous estrogen exposure that increases endometrial cancer risk 4, 5, 2

Common Pitfalls to Avoid

  • Never use estrogen therapy alone in anovulatory bleeding except for profuse bleeding unresponsive to progestin, as it increases the risk of endometrial hyperplasia and cancer from unopposed estrogen 5

  • Progestins with anti-androgenic effects should be avoided in patients with potential hypoandrogenism, though this is less relevant in adolescent anovulatory bleeding 3

  • Ensure pregnancy is ruled out before initiating any hormonal therapy in reproductive-age patients 6, 7

Alternative Options if Norethisterone Fails

  • Combined hormonal contraceptives (CHCs) are effective for ovulatory dysfunction bleeding and can be used if the patient also requires contraception 6, 2

  • NSAIDs can be added to reduce bleeding volume further when used with hormonal therapy 3, 6

  • If bleeding persists despite medical therapy, further investigation with imaging or hysteroscopy is indicated to rule out structural causes 6, 7

References

Research

Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens.

The Australian & New Zealand journal of obstetrics & gynaecology, 1990

Research

Management of abnormal uterine bleeding.

American journal of obstetrics and gynecology, 1996

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Abnormal Uterine Bleeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initial Management of Abnormal Uterine Bleeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.